If you run a pharmacovigilance team, you know the equation well: the volume of Individual Case Safety Reports (ICSRs) grows every year, EMA deadlines are non-negotiable (15 days for serious unexpected adverse reactions, 90 days for periodic ones), and the team is the same size it was three years ago.
The outcome is predictable: chronic overtime, high turnover in specialized profiles that are hard to replace, and the constant pressure of knowing that any deadline miss triggers a regulatory authority procedure.
At Delbion we have over 15 years of experience in IT and cybersecurity applied to regulated environments. For the past two years, we have been implementing AI agents in pharmaceutical groups that need to scale their pharmacovigilance capacity without scaling their headcount — and without sacrificing the integrity of the regulatory process.
This article explains what part of pharmacovigilance can be automated today, how it works in practice, and what security and compliance guarantees are essential.
Why Traditional Pharmacovigilance Doesn't Scale
Pharmacovigilance is a high-volume, high-precision, high-regulatory-consequence process. All three factors together create a bottleneck that is difficult to resolve with traditional approaches.
The volume of ICSRs has grown steadily over the last decade, driven by pharmaceutical market growth, increased active pharmacovigilance and greater patient awareness for reporting adverse reactions.
The scale problem in numbers: A mid-sized pharmaceutical group with 20-30 products in the European market can receive between 5,000 and 15,000 ICSRs annually. If each case requires an average of 45 minutes of manual work, we are talking about 3,750 to 11,250 hours of specialist pharmacist work — just for case processing.
What AI Agents Automate in Pharmacovigilance
AI agents do not replace the pharmacist responsible for the causality decision — that remains a human responsibility and should stay that way. What they automate is the extraction, structuring, coding and tracking of the data the pharmacist needs to make that decision.
1. Initial ICSR Processing
The agent receives ICSRs from their various input sources (web forms, HCP emails, scientific literature, clinical study records) and performs the initial triage: extracts structured data, detects whether it is a serious or non-serious case, and identifies the applicable reporting requirements according to EMA deadlines.
2. Automatic MedDRA Coding
MedDRA coding is one of the most time-intensive processes. The agent automatically codes terms into the correct MedDRA hierarchy (LLT, PT, HLT, HLGT, SOC) with a precision rate above 88%. The pharmacist validates and adjusts if necessary — instead of coding from scratch.
Real case: pharmaceutical group with European portfolio. A laboratory we work with was manually processing between 400 and 600 ICSRs monthly with a team of 6 people. Volume peaks generated systematic overtime. After implementing the agent, the same team manages the same volume without overtime — and devotes the freed time to reviewing emerging signals.
3. Continuous Safety Signal Monitoring
The agent continuously monitors EudraVigilance, scientific literature on PubMed/Embase, specialized social networks and patient forums, and generates alerts when it detects signals requiring evaluation. This goes from being a weekly/monthly task to a real-time process.
4. PSUR and RMP Preparation
The agent generates the PSUR draft from period data: exposure statistics, ICSR analysis by reaction type, review of identified signals, and benefit-risk balance update. The specialist pharmacist reviews, adds the clinical judgment analysis, and signs.
Free Assessment
How many ICSRs does your team process manually each month?
In 60 minutes we calculate the automation potential in your pharmacovigilance process: automatable cases, hour reduction, and EMA compliance guarantees.
Request Free Assessment →Results in Numbers
| Activity | Manual Process | With AI Agent | Savings |
|---|---|---|---|
| ICSR Processing | 25-40 min/case | 5-8 min (review) | ~75% |
| MedDRA Coding | 15-30 min/case | 2-3 min (validation) | ~85% |
| Triage and Classification | 10-15 min/case | Automatic | ~90% |
| Signal Monitoring | Weekly/monthly | Continuous (real-time alerts) | Preventive |
| PSUR Draft | 3-5 weeks | 1-2 weeks (review and sign) | ~60% |
| Causality Assessment | Pharmacist | Pharmacist (not automatable) | N/A |
EMA and GVP Compliance: What the Agent Must Respect
An AI agent in pharmacovigilance must be designed with the regulatory framework as a technical constraint, not as an afterthought.
Complete traceability of each agent decision
The agent logs each action: what data it processed, what coding it proposed, what signals it identified. If a regulatory authority asks, there is an auditable log to justify it.
Human-in-the-loop for every regulatorily significant decision
The agent automates the process, but does not sign the ICSR or PSUR. Validation and signature by a qualified pharmacist is a non-negotiable requirement under GVP.
Clinical and personal data security
We design agents with anonymization in the processing layer, data encryption in transit and at rest, and granular access controls. Data never leaves the European environment.
Periodic agent performance validation
We include a quarterly performance validation process: coding precision rate, quality of identified signals, and correct severity classification.
On the EU AI Act in pharmaceutical applications: The EU AI Regulation classifies systems that assist in drug safety risk assessment as high-risk applications. At Delbion we design pharmacovigilance agents to comply with the AI Act by design, with all the necessary technical documentation.
The Implementation Process: From Zero to Production
Weeks 1-2: Assessment and agent design
Analysis of your product portfolio, ICSR volume, case input sources, and pharmacovigilance management system (Argus, ARISg, Ennov, etc.).
Weeks 3-5: Training with historical data
The agent is trained with resolved historical ICSRs — cases where the correct output is known. We validate quality before touching new cases.
Weeks 6-8: Parallel production
The agent enters production but the manual process continues in parallel. We compare outputs, identify discrepancies and adjust. At the end there is documented cross-validation.
Week 9+: Handover and ongoing support
The manual process is retired and the agent takes over the full flow. Delivery of technical documentation for the quality system. Start of monthly support.
What Pharmacovigilance Directors Ask
Will an EMA inspection accept AI-processed cases?
Yes, as long as GVP requirements are met: process traceability, human validation of the final decision, and documentation of the system used. The agent generates all necessary documentation to demonstrate compliance.
What if the agent incorrectly classifies a serious case?
The agent flags cases with high uncertainty as "requires priority review" and escalates to the pharmacist. Serious cases are always reviewed before any notification.
Can the agent handle ICSRs in multiple languages?
Yes. The agent processes cases in the main European languages with integrated translation and data extraction. MedDRA coding is always done in English, the EudraVigilance standard.
What changes in the team: Pharmacovigilance directors we work with describe the change this way: their teams go from being case processors to being signal analysts. The high-value work — interpreting patterns, evaluating emerging risks — was what professionals wanted to do but didn't have time for. Now they have time.
The Next Step
If your pharmacovigilance team is managing the current volume with overtime or with a growing backlog, the first step is a 60-minute Assessment with our team. We analyze your ICSR volume, your product portfolio, your current system, and show you exactly what part of the process is automatable.
No commitment, no generic sales pitch. Just specific analysis for your organization and your portfolio.